Experts in Polymer Therapeutics

Our founding scientific and management teams have deep experience in polymer drug development. Serina co-founders Harris and Bentley developed the first-generation of PEGylated drugs at Shearwater Polymers. PEG became widely accepted as the standard technology platform for improving biological drugs.

Our Leadership

Randall Moreadith, MD, PhD
President, CEO

Former Chief Development Officer, Nektar Therapeutics

Co-Founder, ThromboGenics, Ltd. (now Oxurion)

25 Year Biotechnology Executive (led polymer therapeutics programs for 13 years)

Led $36M+ raise at Serina

Michael Bentley, PhD
Co-Founder, CSO

VP, Research Group, Shearwater Polymers, and VP, Research Nektar Therapeutics

Fulbright Senior Research Scholar

Fellow, Japan Agency for Science & Technology

Professor and Chairman, Dept of Chemistry University of Maine

Tacey Viegas, PhD
Chief Operating Officer

Senior executive in the pharma industry for > 20 years

Expert in CMC, drug delivery, pharmacology

Co-inventor on multiple polymer therapeutics patents

Advanced multiple product candidates through IND

J. Milton Harris, PhD
Co-Founder, Chairman

Founded Shearwater Polymers, Inc. in 1992

200 publications and 75 patents

2005 Recipient of the Nagai Innovation Award

Member, Swedish Academy of Engineering Sciences

Led $36M+ raise at Serina

Board of Directors & Advisory

Board of Directors

J. Milton Harris, PhD

Founder, Chairman of the Board

Michael Bentley, PhD

Founder, Chief Scientific Officer

Barbara Fisk


James R. Hudson, Jr.


Lonnie S. McMillian

Director Emeritus

Miguel Loya


Randall W. Moreadith, MD, PhD

President, Chief Executive Officer

Clinical Advisory Board

C. Warren Olanow, MD

William K. Schmidt, PhD

Join our revolution

Our scientists are driving the next generation of polymer science.   Learn more about our mission to engineer the future of drug delivery.